Lewy Body Diseases (LBDs) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Lewy Body Diseases (LBDs) Market Outlook

Thelansis’s “Lewy Body Diseases (LBDs) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Lewy Body Diseases treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Lewy Body Diseases (LBDs) Overview

Lewy body diseases (LBDs) encompass a range of clinical conditions, including Parkinson's disease (PD), Parkinson's disease dementia (PDD), and dementia with Lewy bodies (DLB), which collectively exhibit a spectrum of both motor and cognitive symptoms. PD and PDD initially manifest with motor dysfunctions like resting tremors, bradykinesia, and impaired gait, which may progress to cognitive deficits. Conversely, DLB predominantly showcases cognitive impairments, often evolving to encompass Parkinsonian features like those observed in PD. The distinctive pathological hallmark of LBD involves the presence of intraneuronal aggregations of α-synuclein protein, referred to as Lewy bodies. Alongside Lewy body presence, cases of LBD exhibit discernible nigral depigmentation and striatonigral dopaminergic denervation, factors thought to underlie the extrapyramidal manifestations characteristic of clinical parkinsonism. The precise mechanistic significance of Lewy bodies to the neuronal malfunction and degeneration characteristic of LBD remains unresolved. LBD is the second most prevalent form of dementia following Alzheimer's disease. Onset commonly transpires around age 65, although variations exist concerning earlier or later occurrences. While a definitive cure for LBD remains elusive, therapeutic interventions are available to manage its symptomatic manifestations.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: